Vintafolide (EC145) for the treatment of folate-receptor-α positive platinum-resistant ovarian cancer

Expert Review of Clinical Pharmacology

Volumn 7, Issue 4, 2014, Pages 443-450

  Ambrosio, Allison J ^a   Suzin, Daphne ^a   Palmer, Edwin L ^a   Penson, Richard T ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

chemotherapy; EC145; EC20; etarfolatide; novel

Indexed keywords

ANTINEOPLASTIC AGENT; BMS 753493; DOXORUBICIN; EPOTHILONE DERIVATIVE; ETARFOLATIDE TC 99M; FARLETUZUMAB; FOLATE RECEPTOR 1; FOLIC ACID; IMGN 853; ONX 801; UNCLASSIFIED DRUG; VINTAFOLIDE; PLATINUM COMPLEX; VINCA ALKALOID;

ARTICLE; CANCER CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER PROGNOSIS; CANCER RESISTANCE; CANCER SURVIVAL; CONSTIPATION; DRUG APPROVAL; DRUG EFFICACY; ENDOCYTOSIS; FOOD AND DRUG ADMINISTRATION; HUMAN; ILEUS; MULTICENTER STUDY (TOPIC); NEUROTOXICITY; NONHUMAN; OVARY CANCER; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; ANALOGS AND DERIVATIVES; CLINICAL TRIAL (TOPIC); FEMALE; METABOLISM; OVARIAN NEOPLASMS;

CLINICAL TRIALS AS TOPIC; FEMALE; FOLATE RECEPTOR 1; FOLIC ACID; HUMANS; ORGANOPLATINUM COMPOUNDS; OVARIAN NEOPLASMS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; VINCA ALKALOIDS;

EID: 84903158554     PISSN: 17512433     EISSN: 17512441     Source Type: Journal    
DOI: 10.1586/17512433.2014.909723     Document Type: Article

References (53)

1. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin 2014; 64(1):9-29
2. ACS. American Cancer Society: Cancer Facts & Figures 2013. American Cancer Society, Atlanta, GA, USA; 2013. Available from: Www cancer.org
3. Bookman MA, Greer BE, Ozols RF. Optimal therapy of advanced ovarian cancer: Carboplatin and paclitaxel vs. cisplatin and paclitaxel (GOG 158) and an update on GOG0 182-ICON5. Int J Gynecol Cancer 2003;13(6):735-40 (Pubitemid 38235216
4. Blackledge G, Lawton F, Redman C, Kelly K. Response of patients in phase II studies of chemotherapy in ovarian cancer: Implications for patient treatment and the design of phase II trials. Br J Cancer 1989; 59(4):650-3 (Pubitemid 19111764
5. Eisenhauer EA, Vermorken JB, van Glabbeke M. Predictors of response to subsequent chemotherapy in platinum pretreated ovarian cancer: A multivariate analysis of 704 patients [see comments]. Ann Oncol 1997;8(10):963-8 (Pubitemid 27475726
6. Parmar MK, Ledermann JA, Colombo N, et al. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: The ICON4/ AGO-OVAR-2.2 trial. Lancet 2003; 361(9375):2099-106
7. Pujade-Lauraine E, Wagner U, Aavall-Lundqvist E, et al. Pegylated liposomal Doxorubicin and Carboplatin compared with Paclitaxel and Carboplatin for patients with platinum-sensitive ovarian cancer in late relapse. J Clin Oncol 2010; 28(20):3323-9
8. Pfisterer J, Plante M, Vergote I, et al. Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: An intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG. J Clin Oncol 2006;24(29):4699-707 (Pubitemid 46630933
9. Naumann RW, Coleman RL. Management strategies for recurrent platinum-resistant ovarian cancer. Drugs 2011;71(11): 1397-412
10. Burzykowski T, Buyse M. Surrogate threshold effect: An alternative measure for meta-Analytic surrogate endpoint validation. Pharm Stat 2006;5(3):173-86 (Pubitemid 44400217
11. Herzog TJ, Armstrong DK, Brady MF, et al. Ovarian cancer clinical trial endpoints: Society of Gynecologic Oncology white paper. Gynecol Oncol 2014;132(1):8-17
12. Tanner EJ, Chi DS, Eisenhauer EL, et al. Surveillance for the detection of recurrent ovarian cancer: Survival impact or lead-Time bias?. Gynecol Oncol 2010;117(2):336-40
13. FDA. Available from: Www.fda.gov/ downloads/Drugs/./Guidances/ucm071590. pdf [Last accessed 1 January 2014] Regulations CoF. 21 CFR part 314, subpart H and 21 CFR part 601, subpart E
14. Oza AM, Castonguay V, Tsoref D, et al. Progression-free survival in advanced ovarian cancer: A Canadian review and expert panel perspective. Curr Oncol 2011;18(Suppl 2): S20-7
15. Rustin GJ, van Der Burg ME, Griffin CL, et al. Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/ EORTC 55955): A randomised trial. Lancet 2010;376(9747):1155-63
16. Wei W, Dizon D, Vathipadiekal V, Birrer MJ. Ovarian cancer: Genomic analysis. Ann Oncol 2013;24(Suppl 10): X7-15
17. Lim D, Oliva E. Precursors and pathogenesis of ovarian carcinoma. Pathology 2013;45(3):229-42
18. Cancer Genome Atlas Research N. Integrated genomic analyses of ovarian carcinoma. Nature 2011;474(7353):609-15
19. Banerjee S, Kaye SB, Ashworth A. Making the best of PARP inhibitors in ovarian cancer. Nat Rev Clin Oncol 2010;7(9): 508-19
20. Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res 2014;20(3):764-75
21. Farber S, Diamond LK. Temporary remissions in acute leukemia in children produced by folic acid antagonist, 4-Aminopteroyl-glutamic acid. N Engl J Med 1948;238(23):787-93
22. Miller DS, Blessing JA, Krasner CN, et al. Phase II evaluation of pemetrexed in the treatment of recurrent or persistent platinum-resistant ovarian or primary peritoneal carcinoma: A study of the Gynecologic Oncology Group. J Clin Oncol 2009;27(16):2686-91
23. Antony AC. The biological chemistry of folate receptors. Blood 1992;79(11):2807-20
24. Chen YL, Chang MC, Huang CY, et al. Serous ovarian carcinoma patients with high alpha-folate receptor had reducing survival and cytotoxic chemo-response. Mol Oncol 2012;6(3):360-9
25. Sandoval RM, Kennedy MD, Low PS, Molitoris BA. Uptake and trafficking of fluorescent conjugates of folic acid in intact kidney determined using two-photon microscopy. Am J Physiol Cell Physiol 2004;287:C517-26
26. Leamon CP, Reddy JA, Vlahov IR, et al. Comparative preclinical activity of the folate-Targeted Vinca alkaloid conjugates EC140 and EC145. Int J Cancer 2007; 121(7):1585-92 (Pubitemid 47328719
27. Toffoli G, Cernigoi C, Russo A, et al. Overexpression of folate binding protein in ovarian cancers. Int J Cancer 1997;74(2): 193-8 (Pubitemid 27234510
28. Gabizon AA. Pegylated liposomal doxorubicin: Metamorphosis of an old drug into a new form of chemotherapy. Cancer Invest 2001;19(4):424-36 (Pubitemid 32525189
29. Ferrandina G, Ludovisi M, Lorusso D, et al. Phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in progressive or recurrent ovarian cancer. J Clin Oncol 2008;26(6): 890-6 (Pubitemid 351398081
30. Mutch DG, Orlando M, Goss T, et al. Randomized phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer. J Clin Oncol 2007;25(19):2811-18 (Pubitemid 47123191
31. Colombo N, Kutarska E, Dimopoulos M, et al. Randomized, open-label, phase III study comparing patupilone (EPO906) with pegylated liposomal doxorubicin in platinum-refractory or -resistant patients with recurrent epithelial ovarian, primary fallopian tube, or primary peritoneal cancer. J Clin Oncol 2012;30(31):3841-7
32. Siu MK, Kong DS, Chan HY, et al. Paradoxical impact of two folate receptors, FRalpha and RFC, in ovarian cancer: Effect on cell proliferation, invasion and clinical outcome. PLoS ONE 2012;7(11):e47201
33. Leamon CP, Reddy JA, Vlahov IR, et al. Comparative preclinical activity of the folate-Targeted Vinca alkaloid conjugates EC140 and EC145. Int J Cancer 2007; 121(7):1585-92 (Pubitemid 47328719
34. Lorusso PM, Edelman MJ, Bever SL, et al. Phase I study of folate conjugate EC145 (Vintafolide) in patients with refractory solid tumors. J Clin Oncol 2012;30(32): 4011-16
35. Naumann RW, Coleman RL, Burger RA, et al. PRECEDENT: A Randomized Phase II Trial Comparing Vintafolide (EC145) and Pegylated Liposomal Doxorubicin (PLD) in Combination Versus PLD Alone in Patients With Platinum-Resistant Ovarian Cancer. J Clin Oncol 2013;31(35):4400-6
36. Kamen BA, Smith AK. Farletuzumab, an anti-folate receptor alpha antibody, does not block binding of folate or anti-folates to receptor nor does it alter the potency of anti-folates in vitro. Cancer Chemother Pharmacol 2012;70(1):113-20
37. Spannuth WA, Sood AK, Coleman RL. Farletuzumab in epithelial ovarian carcinoma. Expert Opin Biol Ther 2010;3): 431-7
38. Kurkjian C, LoRusso P, Sankhla KK, et al. A phase I, first-in-human study to evaluate the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of IMGN853 in patients (Pts) with epithelial ovarian cancer (EOC) and other FOLR1-positive solid tumors. J Clin Oncol 2013;31(Suppl): Abstract 2573
39. Armstrong DK, White AJ, Weil SC, et al. Farletuzumab (a monoclonal antibody against folate receptor alpha) in relapsed platinum-sensitive ovarian cancer. Gynecol Oncol 2013;129(3):452-8
40. Kelemen LE, Sellers TA, Keeney GL, Lingle WL. Multivitamin and alcohol intake and folate receptor alpha expression in ovarian cancer. Cancer Epidemiol Biomarkers Prev 2005;14(9):2168-72 (Pubitemid 41603263
41. Jackman AL, Jansen G, Ng M. Folate receptor targeted thymidylate synthase inhibitors. In: Targeted Drug Strategies for Cancer and Inflammation. Springer Science and Business Media; 2011. p. 93-117
42. Peethambaram PP, Hartmann LC, Goss GD, et al. A phase I pharmacokinetic and safety analysis of epothilone folate (BMS-753493): A first-in-human clinical experience of a folate receptor-Targeted chemotherapeutic agent dosed once daily on Days 1, 2, 3, and 4 of a 21-day cycle. J Clin Oncol 2010;28(Suppl):Abstract e13005
43. Covello K, Flefleh C, Menard K, et al. Preclinical pharmacology of epothilone-folate conjugate BMS-753493, a tumor-Targeting agent selected for clinical development [Abstract 2326]. AACR 2008 99th AACR Annual Meeting; 12-16 April 2008; San Diego, CA, USA
44. Naik PK, Lopus M, Aneja R, et al. In silico inspired design and synthesis of a novel tubulin-binding anti-cancer drug: Folate conjugated noscapine (Targetin). J Comput Aided Mol Des 2012;26(2):233-47
45. Li TS, Yawata T, Honke K. Efficient siRNA delivery and tumor accumulation mediated by ionically cross-linked folic acidpoly (ethylene glycol)-chitosan oligosaccharide lactate nanoparticles: For the potential targeted ovarian cancer gene therapy. Eur J Pharm Sci 2014;52:48-61
46. Reber J, Haller S, Leamon CP, Muller C. 177Lu-EC0800 combined with the antifolate pemetrexed: Preclinical pilot study of folate receptor targeted radionuclide tumor therapy. Mol Cancer Ther 2013; 12(11):2436-45
47. Nukolova NV, Oberoi HS, Cohen SM, et al. Folate-decorated nanogels for targeted therapy of ovarian cancer. Biomaterials 2011;32(23):5417-26
48. Kandalaft LE, Powell DJ Jr, Coukos G. A phase I clinical trial of adoptive transfer of folate receptor-Alpha redirected autologous T cells for recurrent ovarian cancer. J Transl Med 2012;10:157
49. Study for women with platinum resistant ovarian cancer evaluating EC145 in combination with Doxil- (PROCEED). Available from: Www clinicaltrials.gov/ ct2/ results?term=NCT01170650&Search=Search
50. An efficacy and safety study of MORAb-003 in platinum-resistant or refractory relapsed ovarian cancer. Available from: Www clinicaltrials.gov/ct2/ results?. term=NCT00738699&Search=Search
51. First-in-human study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of IMGN853 in adults with ovarian cancer and other FOLR1-positive solid tumors. Available from: Www clinicaltrials.gov/ ct2/results?. term=NCT01609556&Search=Search
52. A phase 1/2 study of epofolate (BMS-753493) in subjects with advanced cancer (Schedule 2). Available from: Www. clinicaltrials.gov/ct2/results?. term=NCT00550017&Search=Search
53. A phase 1/2 study of epofolate (BMS-753493) in subjects with advanced cancer (Schedule 1). Available from: Www. clinicaltrials.gov/ct2/results?. term=NCT00546247&Search=Search